We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Cambridge Cognition Holdings Plc | LSE:COG | London | Ordinary Share | GB00B8DV9647 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 52.00 | 51.00 | 53.00 | 52.00 | 52.00 | 52.00 | 3,759 | 08:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 12.61M | -409k | -0.0117 | -44.44 | 18.12M |
Date | Subject | Author | Discuss |
---|---|---|---|
17/8/2016 06:44 | Cambridge Cognition Holdings (COG) 100% Buy 17th August 2016 | dice1950 | |
17/8/2016 05:20 | The Daily Mail Cambridge Cognition Holdings (COG) rocketed 30 per cent On the alternative market Cambridge Cognition climbed as it announced results from a study into the effectiveness of using gadgets to access brain health. The neuroscience business said wearable technology such as the Apple Watch and Microsoft Band could be used to accurately measure cognitive performance in everyday life with its software. Around 450million people across the world are living with some form of mental illness, the firm said, and the cost of treatment and care was likely to double by 2030. Cambridge said its Cognition Kit software could help doctors and patients better understand and manage day-to-day brain health by measuring key factors in real time. Participants in a study wore wearable technology which monitored their stress levels and physiological activity on a day-to-day basis and while they completed micro tests to measure attention, memory, mood and reaction speed. Shares rocketed 30 per cent, or 12p to 52.5p. | dice1950 | |
16/8/2016 08:10 | doing well since placing. Great statement today. Should be able to use that validation to monetise relationships going forward. well done to the new team! | maccamcd | |
02/6/2016 09:24 | a good watch, panorama 8pm to-night highlights the problems in coping with dementia, diagnosis at 50yrs could mean his disease may have started around the age 30/35yrs 50ml worldwide, 2ml in UK within ten yrs the critical TIME factor is diagnosis to medication, cases of those coming off/given up on medication are known to reach stage 6 within just two/three months shocking news on NHS with patient reviews after diagnosis at one visit per year, | mike24 | |
19/5/2016 18:12 | Read Hybridan's note on CAMBRIDGE COGNITION HOLDINGS (COG), out this morning, by visiting hxxps://www.research "The specialist developer and distributor of computerised neuropsychological tests including those enabling the early detection of dementia, last month completed a placing raising gross proceeds of £1.25m. The company’s core customer base comprises leading academic research institutes and pharmaceutical and biotechnology companies. The development focus is now shifting to high volume measurement which will facilitate penetration into the healthcare market which is currently the company’s smallest revenue generator but..." | thomasthetank1 | |
17/3/2016 12:05 | Spotted this company yesterday after the fall, down again today I see, I may be tempted around 50p however the finances are a concern now, the fact that it is loss making is not surprising however cash is being eroded and a fundraising must be a possibility, has this company raised cash already since being listed ?? Thanks | eastbourne1982 | |
16/3/2016 08:58 | Having to look long term on this, especially after todays drop. Having seen the effects and cost due to not detecting early, development and implementation of this type of technology is vital. Early diagnosis is the key. However would like to forget the price I entered this share (no pun intended). | petes5 | |
16/3/2016 08:56 | Not doing a great job for shareholders though. | gargoyle2 | |
16/3/2016 08:50 | follow the news flow, what is coming to light is dementia problems in people in their thirties due to taking so called recreational drugs, the problem being more acute in NZ/Australia due to drugs being stronger, so early diagnosis is becoming evermore critical, | mike24 | |
19/1/2016 14:16 | There has to be some news leaking here. | gargoyle2 | |
19/1/2016 13:50 | Been looking at the company's website today. They still have Nick Kerton shown as the CEO, whereas actually he stepped down due to a serious medical condition in July last year. Stephen Powell was appointed interim CEO, but he is nowhere to be seen on the website. I wonder if Kerton's absence is affecting the company. | gargoyle2 | |
19/1/2016 13:23 | ell its the 2nd substantive fall in a relatively short time; don't know what to make of it. | janeann | |
19/1/2016 12:14 | Falling heavily on very small volumes here. Anyone topping up? The November statement said that "2016 is expected to be a year of material growth as the Company continues to make significant commercial and technological advances". I can't see any reason on fundamentals for the fall. | gargoyle2 | |
11/1/2016 16:01 | A little unexpected top up opportunity. That should help the share price | martinthebrave | |
11/1/2016 15:26 | Volume is tiny, perhaps just a clumsy seller in a very jittery market? | phowdo | |
11/1/2016 15:09 | off a whopping 20% on no news and all since 14.00. Some thing going on behind the scenes? | janeann |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions